Journal Scans
Retreatment With Bortezomib Alone or in Combination for Patients With Multiple Myeloma Following an Initial Response to Bortezomib
Rechallenge With Bortezomib in Progressive Multiple Myeloma
R Sood, H Carloss, R Kerr, J Lopez, M Lee, M Druck, IB Walters, SJ Noga
20090630
2009 Jul 30
Am J Hematol
Retreatment With Bortezomib Alone or in Combination for Patients With Multiple Myeloma Following an Initial Response to Bortezomib
Am J Hematol. 2009 Jul 30;84(10):657-660, R Sood, H Carloss, R Kerr, J Lopez, M Lee, M Druck, IB Walters, SJ Noga
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Bortezomib is currently the only single agent proven to prolong overall survival (OS) in patients with relapsed multiple myeloma (MM). The drug is active both as monotherapy and when given concomitantly with dexamethasone, doxorubicin (and pegylated liposomal doxorubicin), thalidomide, and other drugs. Rechallenge with bortezomib-containing regimens also appears be effective in patients with MM and is not associated with increased toxicity. Thus, a rationale exists for evaluating the use of re-treatment...
